(b) conversely, addition of an ACE inhibitor to a dihydroinhibitors slow progression of diabetic nephropathy to a pyridine CCB (DCCB) yields effects on proteinuria simigreater extent than other antihypertensive agents when lar to the ACE inhibitor alone. Therefore, addition of an blood pressure (BP) is reduced to levels below 140/90 ACE inhibitor to a DCCB demonstrates protection mm Hg. Recent studies also demonstrate that nondihyagainst the effects of DCCB alone. Addition of an ACE dropyridine calcium channel blockers (NDCCBs) slow inhibitor to a NDCCB does not potentiate the preserprogression of diabetic nephropathy in people with prevation of renal morphology associated with progression existing renal insufficiency secondary to non-insulin of diabetic nephropathy when compared to either of its dependent diabetes mellitus. The combined effects of components alone. Conversely, a DCCB/ACE inhibitor both a CCB and ACE inhibitor have recently been examcombination yields morphologic results similar to the ined in both animal models of diabetes as well as ACE inhibitor alone. Taken together these results sugpatients with established diabetic nephropathy. These gest that ACE inhibitors when combined with a NDCCB studies demonstrate the following points: (a) at comparesult in greater reductions in proteinuria, and similar rable BP levels, a combination of an ACE inhibitor with preservation of renal morphology when compared to a NDCCB result in a greater reduction in proteinuria either of its components alone. when compared to either components alone; and
Introduction
however, studies with angiotensin-converting Diabetic nephropathy will occur in approximately enzyme (ACE) inhibitors demonstrate a marked 40% of the more than 16 million diabetic patients slowing in the progression of nephropathy, an effect, in the United States. 1 This number of patients is in part, independent of blood pressure (BP) comparable to the number with heart failure, crereduction. [6] [7] [8] [9] This associated effect may be due to ating a major public health problem in the US. Moreunique properties of ACE inhibitors. These include over, the morbidity associated with diabetic nephroa reduction in glomerular permeability to glycated pathy is quite high. Such patients have a higher risk albumin as well as a reduction in intraglomerular from cardiovascular events, infection, death and pressure. [9] [10] [11] [12] limb loss secondary to gangrene, when compared to Few long-term studies with calcium channel the general population. In addition, these patients blockers (CCBs) have been carried out to assess their have a higher incidence of depression when comeffects on progression of diabetic nephropathy. pared to the normal population; this is especially CCBs have diverse effects on progression of diabetic true once they start dialysis. Lastly, from a socionephropathy. Dihydropyridine CCBs (nifedipineeconomic standpoint, delaying the onset of dialysis like agents), in general, do not reduce surrogate marwould save approximately $55 000 per patient per kers of renal disease progression. Specifically, they year. 2, 3 Slowing progression of diabetic nephropathy do not reduce proteinuria. [13] [14] [15] [16] [17] [18] Moreover, in animal will potentially have far reaching positive results for studies they do not prevent development of glonot only patients with this problem but society in merulosclerosis. effect of CCBs on renal membrane permeability and glomerular scarring has been attributed to several dependent diabetes. [4] [5] [6] Patients with non-insulin dependent diabetes have also received positive etiologies including: a differential distribution of calcium channels and specific effects on synthesis benefits from ACE inhibitors. However, the data is less consistent. of various matrix proteins. 26 The specific effects of either ACE inhibitors or CCBs alone or combined CCBs must be viewed as a heterogeneous group of antihypertensive agents. For simplicity they can be will be discussed. divided into two groups, dihydropyridine or (nonheart rate lowering) agents and nondihydropyridine
ACE inhibitors
(heart rate lowering CCBs). The effects of these two subclasses on renal permeability and glomerular Mesangial matrix expansion is the earliest morphologic change to occur in people with diabetic morphology are divergent. There are over 20 animal studies with dihydropyrnephropathy. 27 Animal studies have shown specific effects of ACE inhibitors on mesangial matrix proidine CCBs demonstrating no reduction in glomerular scarring or proteinuria. 15, 16, 24, 26 These studies tein synthesis. Specifically, ACE inhibitors have been shown to reduce the increased synthesis of have been carried out not only in animal models of diabetes but also in models of renal insufficiency. fibronectin, laminin and collagen IV synthesis in animal models of diabetes. 28 This attenuated synConversely, animal studies with nondihydropyridine CCB (NDCCB) generally demonstrate a uniform thesis in matrix proteins correlates with a reduction in proteinuria and a reduction in glomerulosclerosis preservation of renal morphology and an attenuated rise in the amount of proteinuria. 15, 16, 24, 26 The in all animal models studied.
Very few human studies have attempted to evalureasons for these differences are diverse and may relate to direct effects on glomerular permeability. ate the correlation between the development of glomerulosclerosis and changes in proteinuria. This
These animal data are, in part, supported by long term clinical studies with NDCCBs. Studies of has been assessed in animal models. In a recent study, Taft et al 29 followed patients for 4 years. greater than 2 years duration demonstrate a faster rate of decline in renal function in groups ranPatients had a biopsy prior to follow-up and a repeated biopsy at the end of this time period. 29 domized to dihydropyridine calcium channel blockers compared to ACE inhibitors. 4, 6, 28, 31 One excepPatients had their BPs treated with regiments that either contained ACE inhibitors or other convention, however, is a recent 3-year study in noninsulin dependent diabetic patients randomized to tional therapy. At the end of this time period they were unable to show a significant difference in the either an ACE inhibitor or amlodipine. 25 In this small study there were similar reductions in albumiamount of mesangial expansion of glomerulosclerosis between the groups. However, the group nuria and similar stabilization of renal function as assessed by change in glomerular filtration rate receiving the ACE inhibitor tended to have less glomerulosclerosis and interstitial fibrosis. Therebetween the two groups. This is the only long-term study with a long-acting dihydropyridine CCB fore, one could interpret this data as an insufficient follow-up time in a small number of patients to which shows a similar benefit to ACE inhibition on surrogate end points. Conversely, all clinical studies assess a meaningful change. However, a recent analysis of all such small studies was performed. 24 with either verapamil or diltiazem demonstrate reductions in proteinuria and a slowed progression This analysis showed that a reduction in proteinuria correlated with a blunted increase in glomerular of disease to levels similar to those seen with ACE inhibitors. This data however, was established in scarring.
ACE inhibitors reduce glomerular permeability as people with chronic renal insufficiency secondary to non-insulin dependent diabetes. manifested clinically by their reduction in proteinuria. Three separate meta-analyses demonstrate that ACE inhibitors reduce proteinuria to a degree
ACE/CCB combinations
greater than what would be predicted by BP reduction alone. [4] [5] [6] Both animal and human studies Recent animal studies have taken advantage of the renal effects seen with both ACE inhibitors and demonstrate that this reduction in proteinuria is due to a reduction in diabetes induced increases in CCBs, by combining them in lower doses to achieve similar levels of BP control. 18,19,32,33 These combiglomerular permeability.
ACE inhibitors largely decrease protein shunting nations have recently been studied with regard to their effects on proteinuria and progression to gloat the membrane level as well as increase or help to restore the loss of anionic charge selectivity. As a merulosclerosis. Recent animal studies in remnant kidney models have evaluated the effects of both the result, these drugs decrease the leakage of glycated albumin through the membrane. When glycated dihydropyridine and NCCCB in combination with an ACE inhibitor vs either of the components alone albumin is exposed to normal cells it results in cellular injury, in part, through free radical generon progression to glomerulosclerosis and proteinuria. These studies were performed in the remation. 10 Hence, reduced exposure of glycated albumin to the renal cells should provide protection nant kidney model as well as a hypertensive model in the rat. Studies using amlodipine and benazapril against injury.
Clinically, ACE inhibitors have also shown an alone or in combination demonstrate no protection against the increases in proteinuria with amlodipine advantage over other BP agents on slowing progression of diabetic nephropathy.
7-9,30 However, the or glomerulosclerosis while the ACE inhibitor prevents both processes. 33 Combinations of these preponderance of the data is in patients with insulin weeks the study demonstrated that while the indi- 
